Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: The role of quinolones in oropharyngeal tularemia
dc.contributor.author | Meriç, Meliha | |
dc.contributor.author | Willke, Ayse | |
dc.contributor.author | Finke, Ernst-Jurgen | |
dc.contributor.author | Grunow, Roland | |
dc.contributor.author | Sayan, Murat | |
dc.contributor.author | Erdoğan, Sarper | |
dc.contributor.buuauthor | Gedikoğlu, Suna | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 6603407548 | en_US |
dc.date.accessioned | 2021-11-22T11:19:55Z | |
dc.date.available | 2021-11-22T11:19:55Z | |
dc.date.issued | 2008-01 | |
dc.description.abstract | Tularemia outbreaks have occurred in various regions of Turkey in recent years. In this study, clinical (145 patients) and laboratory (97 patients) features of patients with oropharyngeal tularemia were evaluated during the tularemia outbreak in the district of Golcuk in Kocaeli, Turkey. We analyzed the risk factors for therapeutic failure and prolonged recovery time, and compared the efficacy of three antibiotic groups, namely aminoglycoside, tetracycline and quinolone. The most common physical sign and laboratory findings in patients were lymphadenopathy (LAP) and increased erythrocyte sedimentation rate, respectively. Treatment failure was observed in 55 of the 145 (38%) patients during one-year follow-up and the most successful results were obtained in the quinolone group. It was determined that antimicrobial therapy initiated 14 days after onset of symptoms was a statistically significiant risk factor, reducing the success rate (p=0.0001, OR=13.10, 95% CI=5.69-30.15) and prolonging the recovery period (p=0.001, OR=3.23, 95% CI=1.63-6.40) in oropharyngeal tularemia cases. These results suggest that antimicrobial treatment should be started early, and quinolones such as moxifloxacin and ciprofloxacin seem to be new alternatives in the treatment of oropharyngeal tularemia. | en_US |
dc.identifier.citation | Meriç, M. vd. (2008). ''Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia''. Apmis, 116(1), 66-73. | en_US |
dc.identifier.endpage | 73 | tr_TR |
dc.identifier.issn | 0903-4641 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 18254782 | tr_TR |
dc.identifier.scopus | 2-s2.0-38849182885 | tr_TR |
dc.identifier.startpage | 66 | tr_TR |
dc.identifier.uri | https://doi.org/10.1111/j.1600-0463.2008.00901.x | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0463.2008.00901.x | |
dc.identifier.uri | http://hdl.handle.net/11452/22754 | |
dc.identifier.volume | 116 | tr_TR |
dc.identifier.wos | 000252805500010 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Apmis | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oropharyngeal tularemia | en_US |
dc.subject | Quinolones | en_US |
dc.subject | Risk factors | en_US |
dc.subject | Therapeutic failure | en_US |
dc.subject | Francisella-tularensis | en_US |
dc.subject | Ciprofloxacin | en_US |
dc.subject | Susceptibility | en_US |
dc.subject | Fluoroquinolones | en_US |
dc.subject | Children | en_US |
dc.subject | Turkey | en_US |
dc.subject | Immunology | en_US |
dc.subject | Microbiology | en_US |
dc.subject | Pathology | en_US |
dc.subject.emtree | Aminoglycoside antibiotic agent | en_US |
dc.subject.emtree | Ciprofloxacin | en_US |
dc.subject.emtree | Doxycycline | en_US |
dc.subject.emtree | Gentamicin | en_US |
dc.subject.emtree | Moxifloxacin | en_US |
dc.subject.emtree | Quinoline derived antiinfective agent | en_US |
dc.subject.emtree | Streptomycin | en_US |
dc.subject.emtree | Tetracycline | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Antimicrobial therapy | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Convalescence | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Epidemic | en_US |
dc.subject.emtree | Erythrocyte sedimentation rate | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | lymphadenopathy; | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Oropharyngeal tularemia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Statistical significance | en_US |
dc.subject.emtree | Treatment failure | en_US |
dc.subject.emtree | Tularemia | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Anti-Bacterial agents | en_US |
dc.subject.mesh | Blood sedimentation | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Disease outbreaks | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Lymphatic diseases | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Pharyngitis | en_US |
dc.subject.mesh | Quinolones | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Tularemia | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | Francisella Tularensis; Tularemia; Tick Bites | en_US |
dc.subject.wos | Immunology | en_US |
dc.subject.wos | Microbiology | en_US |
dc.subject.wos | Pathology | en_US |
dc.title | Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: The role of quinolones in oropharyngeal tularemia | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |
dc.wos.quartile | Q3 (Pathology) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: